Time to Sell China Biologic Products Holdings, Inc. (CBPO) After The Completion of This Double Bottom Chart Pattern?

January 23, 2018 - By Hazel Jackson

Investors sentiment decreased to 0.03 in Q3 2017. Its down 0.62, from 0.65 in 2017Q2. It dived, as 88 investors sold China Biologic Products Holdings, Inc. shares while 1 reduced holdings. 0 funds opened positions while 3 raised stakes. 1.23 million shares or 91.95% less from 15.29 million shares in 2017Q2 were reported.
Jupiter Asset Mngmt reported 0.51% in China Biologic Products Holdings, Inc. (NASDAQ:CBPO). Employees Retirement Of Ohio holds 0.01% of its portfolio in China Biologic Products Holdings, Inc. (NASDAQ:CBPO) for 10,948 shares. Matthews International Cap Mgmt Lc holds 41,400 shares or 0.16% of its portfolio. Schroder Management Gp has invested 0.16% in China Biologic Products Holdings, Inc. (NASDAQ:CBPO).

The chart of China Biologic Products Holdings, Inc. (CBPO) shows a double bottom with $76.24 target or 8.00 % below today’s $82.87 share price. The 5 months chart pattern indicates high risk for the $2.29B company. It was reported on Jan, 23 by Finviz.com. If the $76.24 price target is reached, the company will be worth $183.04 million less. Double bottoms are rare but powerful chart patterns.

The stock increased 1.77% or $1.44 during the last trading session, reaching $82.87. About 297,976 shares traded or 32.52% up from the average. China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has declined 1.48% since January 23, 2017 and is downtrending. It has underperformed by 18.18% the S&P500.

Analysts await China Biologic Products Holdings, Inc. (NASDAQ:CBPO) to report earnings on February, 22. They expect $1.11 EPS, up 56.34 % or $0.40 from last year’s $0.71 per share. CBPO’s profit will be $30.65 million for 18.66 P/E if the $1.11 EPS becomes a reality. After $1.11 actual EPS reported by China Biologic Products Holdings, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) Ratings Coverage

Among 2 analysts covering China Biologic Products (NASDAQ:CBPO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. China Biologic Products has $162 highest and $128.0 lowest target. $145’s average target is 74.97% above currents $82.87 stock price. China Biologic Products had 6 analyst reports since September 4, 2015 according to SRatingsIntel. As per Tuesday, September 12, the company rating was maintained by Jefferies. Jefferies maintained it with “Buy” rating and $12800 target in Thursday, August 3 report. The stock of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has “Buy” rating given on Friday, September 4 by Jefferies. The company was maintained on Friday, October 13 by Jefferies. The company was maintained on Monday, June 12 by Jefferies.

More notable recent China Biologic Products Holdings, Inc. (NASDAQ:CBPO) news were published by: Prnewswire.com which released: “China Biologic Products Announces Conference Call to Discuss TianXinFu Acquisition” on October 13, 2017, also Prnewswire.com with their article: “China Biologic Announces Completion of Acquisition of TianXinFu from PWM” published on January 03, 2018, Prnewswire.com published: “China Biologic Announces Corporate Update” on January 08, 2018. More interesting news about China Biologic Products Holdings, Inc. (NASDAQ:CBPO) were released by: Prnewswire.com and their article: “China Biologic Announces Effectiveness of Registration Statement and Mailing …” published on May 19, 2017 as well as Nasdaq.com‘s news article titled: “New Silk Road Investment Pte Ltd Buys China Biologic Products Holdings Inc …” with publication date: October 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: